Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Perphenazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 7/20 | 0.88 |
| ▸ | MAPT | P10636 | 8/20 | 0.88 |
| ▸ | LMNA | P02545 | 8/20 | 0.88 |
| ▸ | MAPK1 | P28482 | 7/20 | 0.88 |
| ▸ | ADRA2B | P18089 | 7/20 | 0.88 |
| ▸ | ADRA2C | P18825 | 7/20 | 0.88 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.88 |
| ▸ | HTR2A | P28223 | 7/20 | 0.88 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.88 |
| ▸ | HRH1 | P35367 | 7/20 | 0.88 |
| ▸ | DRD3 | P35462 | 7/20 | 0.88 |
| ▸ | HTR2B | P41595 | 7/20 | 0.88 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.88 |
| ▸ | ADRA2A | P08913 | 6/20 | 0.88 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.88 |
| ▸ | HTR1A | P08908 | 6/20 | 0.88 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.88 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.88 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.88 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Perphenazine SCHEMBL1071642 | 0.94 | LMNA (0.84) | MAPTLMNAMAPK1DRD2ADRA2B | |
| Perphenazine SCHEMBL29461866 | 0.94 | MAPT (1.00) | MAPTLMNAMAPK1DRD2ADRA2B | |
| Perphenazine SCHEMBL29385591 | 0.94 | MAPT (1.00) | MAPTLMNAMAPK1DRD2ADRA2B | |
| Perphenazine SCHEMBL8762197 | 0.94 | MAPT (1.00) | MAPTLMNAMAPK1DRD2ADRA2B | |
| Perphenazine SCHEMBL42125 | 0.94 | MAPT (1.00) | MAPTLMNAMAPK1DRD2ADRA2B | |
| Perphenazine SCHEMBL145754 | 0.92 | MAPT (0.98) | MAPTLMNAMAPK1DRD2ADRA2B | |
| Perphenazine SCHEMBL29846305 | 0.92 | MAPT (0.98) | MAPTLMNAMAPK1DRD2ADRA2B | |
| Perphenazine SCHEMBL140891 | 0.92 | MAPT (0.98) | MAPTLMNAMAPK1DRD2ADRA2B | |
| Perphenazine SCHEMBL871706 | 0.92 | MAPT (0.85) | MAPTLMNAMAPK1DRD2ADRA2B | |
| Perphenazine SCHEMBL871708 | 0.92 | MAPT (0.85) | MAPTLMNAMAPK1DRD2ADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116710083-A | Compositions and methods for treating metabolic disorders | 反应IP控股有限责任公司 | 2023-09-05 | — | — | CN | claimed |
| CN-119384406-A | Compounds of formula (I) | 赛洛私人有限公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-118974044-A | Compounds of formula (I) | 赛洛私人有限公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-118715204-A | Compounds of formula (I) | 普赛洛私人有限公司 | 2024-09-27 | — | — | CN | disclosed |
| CN-118696029-A | Compounds of formula (I) | 普赛洛私人有限公司 | 2024-09-24 | — | — | CN | disclosed |
| CN-112165942-B | Tetrabenazine transdermal delivery device | 新凯治疗有限公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-117580803-A | Silicon particles for drug delivery | 纳康德公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-117561216-A | Silicon particles for hydrogen release | 纳康德公司 | 2024-02-13 | — | — | CN | disclosed |
| CN-117500788-A | Indole derivatives as serotonergic agents for the treatment of diseases associated therewith | 明德赛特制药公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-117242065-A | Indole derivatives as serotonergic agents for the treatment of diseases associated therewith | 明德赛特制药公司 | 2023-12-15 | — | — | CN | disclosed |
| CN-116917305-A | 3-Cyclic Amine-Indole Derivatives as Serotonergic Agents for the Treatment of CNS Disorders | 明德赛特制药公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-116768882-A | Compounds, pharmaceutical compositions and methods of treatment | 奥斯拜客斯制药有限公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-114796209-A | Deutetrabenazine or compositions comprising deutetrabenazine | 奥斯拜客斯制药有限公司 | 2022-07-29 | — | — | CN | disclosed |
| CN-114788824-A | Deutetrabenazine, or compositions comprising deutetrabenazine | 奥斯拜客斯制药有限公司 | 2022-07-26 | — | — | CN | disclosed |
| CN-114767672-A | Deutetrabenazine, or compositions comprising deutetrabenazine | 奥斯拜客斯制药有限公司 | 2022-07-22 | — | — | CN | disclosed |
| CN-107106509-B | Drug delivery system for delivering acid sensitive drugs | 帝斯曼知识产权资产管理有限公司 | 2021-11-30 | — | — | CN | disclosed |
| CN-112165942-A | Transdermal tetrabenazine conveying device | 新凯治疗有限责任公司 | 2021-01-01 | — | — | CN | disclosed |
| CN-111728971-A | D6Solid oral dosage forms of (E) -tetrabenazine, compounds, and pharmaceutical compositions, preparation and treatment methods thereof | AUSPEX PHARMACEUTICALS INC | 2020-10-02 | — | — | CN | disclosed |
| CN-111479813-A | Triazolobenzazepines as vasopressin V1A receptor antagonists | 吉瑞工厂 | 2020-07-31 | — | — | CN | disclosed |